Teriparatide tested against alendronate for back pain in women with osteoporosis
|
|
Teriparatide was tested against alendronate for back pain in women with osteoporosis.
“To compare the effects on back pain of teriparatide versus alendronate,” scientists in the United States conducted a study to “analyze the reporting of back pain in a head to head comparator trial and a followup study. In the comparator trial, women were randomized to receive either daily self-injected teriparatide 40 micro g plus an oral placebo (n=73), or daily oral alendronate 10 mg plus self-injected placebo (n=73).”
“Treatment was for a median 14 months,” stated P. D. Miller and colleagues. “After completion of the comparator trial, 72% of these patients enrolled in a nontreatment followup study. Adverse events were recorded at each comparator trial visit and followup study visit, and the incidence of new or worsening back pain in each group was compared.”
The investigators reported, “During the comparator trial, compared with women randomized to alendronate 10 mg, women randomized to teriparatide 40 micro g had reduced risk for any back pain (relative risk 0.27, 95% CI 0.09-0.82) and moderate or severe back pain (relative risk 0.19, 95% CI 0.04-0.86). The differences in the reporting of back pain between the teriparatide treated women and the alendronate treated women were sustained during an interval including the comparator trial plus 18 additional months.”
“During an interval including the comparator trial plus 30 additional months, teriparatide treated patients had numerically fewer occurrences of back pain and moderate or severe back pain, the authors noted. They concluded, “Compared with women randomized to alendronate 10 mg, women randomized to teriparatide 40 micro g had reduced risk of back pain during the trial and 2.5 years of followup.”
Miller and colleagues published their study in the Journal of Rheumatology (Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol, 2005;32(8):1556-1562).
For additional information, contact P. D. Miller, Colorado Center for Bone Research, 3190 S. Wadsworth Boulevard, Suite 250, Lakewood, CO 80227. E-mail: .(JavaScript must be enabled to view this email address)
Colorado Center for Bone Research, Lakewood, 80227, USA, E-mail: .(JavaScript must be enabled to view this email address).
The publisher’s contact information for the Journal of Rheumatology is: J Rheumatol Publ Co., 920 Yonge Street, Suite 115, Toronto, Ontario M4W 3C7, Canada.
Print Version
Tell-a-Friend comments powered by Disqus
